Amgen reported a strong first quarter with a 9% revenue increase and a 20% rise in adjusted EPS, demonstrating solid performance despite the challenges posed by healthcare reform. Management provided cautious yet confident guidance, emphasizing growth initiatives like Prolia and denosumab while addressing cost mitigation strategies. This balanced outlook is likely to instill investor confidence in the short term.

[1]